WBDE(SZ:002082) Zheng Quan Shi Bao Wang·2025-12-29 14:41Core Viewpoint - Wanbangde's new drug WP107 (Huperzine A oral solution) for treating myasthenia gravis has received ethical approval for its Phase I clinical trial, indicating progress in its drug development pipeline [1][3]. Group 1: Clinical Trial and Regulatory Approvals - Wanbangde's subsidiary has obtained ethical approval from the medical ethics committee of Wenzhou Medical University for the Phase I clinical trial of WP107 [1]. - The company has received orphan drug designation from the FDA for Huperzine A in treating myasthenia gravis and has been granted clinical trial permission for WP107 in January 2025 [3]. - The clinical trial aims to compare the pharmacokinetic characteristics of the oral solution and the injectable form of Huperzine A in healthy subjects [3]. Group 2: Product Development and Market Position - Wanbangde is the sole manufacturer of Huperzine A injection, holding a 24.37% market share in the Huperzine A formulation market, reflecting its technological authority and market exclusivity [2]. - The company is expanding its product matrix with ongoing clinical trials for Huperzine A controlled-release tablets for Alzheimer's disease and other formulations for various neurological conditions [2]. - WP107 is designed to address swallowing difficulties in some myasthenia gravis patients and improve medication adherence in pediatric patients [2]. Group 3: Company Overview and Focus Areas - Wanbangde is headquartered in Taizhou, Zhejiang, focusing on pharmaceutical manufacturing and medical devices across multiple therapeutic areas, including cardiovascular, neurological, respiratory, digestive, and mental health [1]. - The core component of Huperzine A, a novel drug, has received multiple patents globally, including in the US, Europe, and Japan, and has won national awards for its technological innovation [1].